SCHEMBL2410233

SCHEMBL2410233

CC(C)(Sc1nc(CCOc2ccc(-c3ccc(OC(F)(F)F)cc3)cc2)cs1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHMT2 P34897 1/20 0.42
PPARA Q07869 10/20 0.41
PPARG P37231 6/20 0.41
RAB9A P51151 1/20 0.39
PPARD Q03181 4/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38
PTGER4 P35408 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2414869 0.97 PPARA (0.41) SHMT2PPARAPPARGRAB9APPARD
SCHEMBL2412207 0.92 SLC13A5 (0.42) PPARAPPARGHDAC1HDAC2
SCHEMBL2412787 0.92 SHMT2 (0.39) SHMT2PPARAPPARGPPARDHDAC3
SCHEMBL2398837 0.91 RAB9A (0.49) PPARAPPARGRAB9APPARDSMN1; SMN2
SCHEMBL2413916 0.91 SHMT2 (0.38) SHMT2PPARAPPARGPPARDHDAC3
SCHEMBL2413963 0.90 PPARA (0.45) PPARAPPARGPPARD
SCHEMBL2415153 0.90 PPARA (0.45) PPARAPPARGRAB9APPARDSMN1; SMN2
SCHEMBL2419262 0.89 PPARA (0.46) PPARAPPARGRAB9APPARDSMN1; SMN2
SCHEMBL2410536 0.88 PPARA (0.43) PPARAPPARGPPARDSMN1; SMN2
SCHEMBL2412316 0.87 SHMT2 (0.37) SHMT2PPARAPPARGRAB9APPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG SHMT2 865/4885PPARA 1/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.